Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated accordi...
Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, aliroc...
Aims Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but som...
Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
BACKGROUND Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for ma...
BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a prop...
Background: Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a pro...
AimsLipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. ...
Aims Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials....
Aims Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, aliroc...
Aims Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but som...
Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
BACKGROUND Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for ma...
BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a prop...
Background: Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a pro...
AimsLipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. ...
Aims Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials....
Aims Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, aliroc...
Aims Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but som...
Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...